Coronary microvascular dysfunction (CMD) represents a powerful independent predictor of adverse outcome in hypertrophic cardiomyopathy (HCM). No treatment for CMD exists. The angiotensin-converting enzyme (ACE)-inhibitor perindopril improves myocardial blood flow (MBF) in animal models of cardiac hypertrophy and in hypertensive patients. Whether HCM patients with CMD may benefit is unknown.
Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study / De Gregorio, Maria Grazia; Fumagalli, Carlo; Tomberli, Alessia; Baldini, Katia; Puccini, Giulia; d'Amati, Giulia; Foglieni, Chiara; Camici, Paolo G; Sciagrà, Roberto; Olivotto, Iacopo. - In: JOURNAL OF CARDIOVASCULAR MEDICINE. - ISSN 1558-2027. - ELETTRONICO. - Publish Ahead of Print:(2021), pp. 0-0. [10.2459/JCM.0000000000001144]
Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study
De Gregorio, Maria Grazia;Fumagalli, Carlo;Tomberli, Alessia;Puccini, Giulia;Sciagrà, Roberto;Olivotto, Iacopo
2021
Abstract
Coronary microvascular dysfunction (CMD) represents a powerful independent predictor of adverse outcome in hypertrophic cardiomyopathy (HCM). No treatment for CMD exists. The angiotensin-converting enzyme (ACE)-inhibitor perindopril improves myocardial blood flow (MBF) in animal models of cardiac hypertrophy and in hypertensive patients. Whether HCM patients with CMD may benefit is unknown.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Myocardial_blood_flow_in_patients_with.98069.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
256.71 kB
Formato
Adobe PDF
|
256.71 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
